Evidence map›Paper›PMID 24378809›Full record

ArticleInternational journal of oncology2014

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.

Sae Hyun Park, Ji-Ye Song, Yu-Kyung Kim, Jin Hyung Heo, Haeyoun Kang, Gwangil Kim, Hee Jung An, Tae Hoen Kim

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sae Hyun ParkDepartment of Gynecologic Oncology, CHA Gangnam Medical Center, Gangnam-Gu, Seoul 135-907, Republic of Korea.
Ji-Ye SongClinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Yu-Kyung KimClinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Jin Hyung HeoDepartment of Pathology, CHA Bundang Medical Center, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Haeyoun KangDepartment of Pathology, CHA Bundang Medical Center, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Gwangil KimClinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Hee Jung AnClinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
Tae Hoen KimClinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.
CHA University · KRCHA University Bundang Medical Center · KRCHA University Gangnam Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fascin1 (FSCN1) involved in cell motility and filopodia assembly plays important roles in biological processes such as cancer invasion and metastasis of multiple epithelial tumors. High-grade serous ovarian carcinoma (HGSOC) is aggressive and metastatic by acquiring an invasive phenotype and this step requires remodeling of the actin cytoskeleton. Thus, the present study aimed to investigate the expression of fascin1 in HGSOC tissues as well as its clinical significance such as prognostic predictors and its utility of therapeutic target. Fascin1 and β-catenin were evaluated using immunohistochemistry on a tissue microarray of 79 HGSOC. Small interfering RNA (siRNA) approach was used to knock down fascin1 expression in ovarian cancer cell lines to determine whether fascin1 contributes to tumor cell proliferation, migration and invasion. Fascin1 expression levels were determined by western blot analysis after siRNA transfection using two human ovarian cancer cell lines (SKOV3 and OVCAR3). Fascin1 overexpression was significantly correlated with lymph node involvement, distance metastasis and high International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV) (P<0.05). A Kaplan-Meier analysis showed that the fascin1 expression group was significantly associated with poor overall survival (P=0.010). We showed that inactivation of fascin1 by siRNA transfection led to a drop in cell viability, and significantly decreased tumor cell proliferation, migration and invasiveness compared to untransfected cells. We found that fascin1 expression is a potential poor marker of prognosis for patients with HGSOC and knockdown of fascin1 suppresses ovarian cancer cell proliferation and migration, this could be applied for therapeutic targets in ovarian cancer treatment.

Indexed as

AgedBiomarkers, TumorCarrier ProteinsCell Line, TumorCell ProliferationCystadenocarcinoma, SerousFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMicrofilament ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisBiomarkers, TumorCarrier ProteinsFSCN1 protein, humanMicrofilament Proteins

Identifiers

PMID24378809
PMCPMC3928475
OpenAlexW2064750438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.